drugset

drugset / Trial / NCT00400283

A Study Looking Into the Effect of NNC 55-0414 in Subjects With Type 2 Diabetes

NCT00400283 ↗

Phase 1 Completed 23 enrolled Novo Nordisk A/S

RandomizedParallel-groupDouble-blindTreatment

Summary

This trial is conducted in Europe. A seven day dose escalation study in subjects with type 2 diabetes.

Timeline

Start: 2001-01-19
Primary completion: 2001-05-03
Completion: 2001-05-03

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	NNC 55-0414	Unknown	—	—

Indications